Russian telemedicine software developer MVS attracted 325 million rubles from Kama Flow. The funds will be used to expand business abroad, create new products and build production capabilities.

Russian telemedicine software developer MVS raised 325 million rubles from Kama Flow

A representative of the investment company Kama Flow told RB.RU about the deal. He acted as lead investor in a round of 325 million rubles (the company manages the venture fund of the National Technology Initiative).

MVS (Medical Visual Systems, LLC Medical Visualization Systems) is a resident of Skolkovo. The company is implementing “smart” surgical workspaces equipped with equipment control and display systems. The company calls its key development an ecosystem of telemedicine products for managing systems and engineering equipment in operating rooms, intensive care units, and intensive care units.

MVS plans to use the funds raised as a result of the round to expand the business, including abroad, build production capabilities, develop new modules, marketing and sales.

According to the Unified State Register of Legal Entities, the MVS legal entity worked in 2021 with an income of 530.3 million rubles with a net profit of 149.9 million rubles. The company’s products are used in public and private clinics in 16 cities of Russia and Belarus.

Author:

Kirill Bilyk

Source: RB

Previous articleThe authorities discuss the introduction of tokens for the purchase of square meters in apartments
Next articleThe Witcher: Origin of Blood review: an unfortunate and boring look at the larger universe
I am Bret Jackson, a professional journalist and author for Gadget Onus, where I specialize in writing about the gaming industry. With over 6 years of experience in my field, I have built up an extensive portfolio that ranges from reviews to interviews with top figures within the industry. My work has been featured on various news sites, providing readers with insightful analysis regarding the current state of gaming culture.

LEAVE A REPLY

Please enter your comment!
Please enter your name here